Avidity Biosciences, Inc. (RNA) Dividend History

Company News

• Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows

  June closed on a high note for the stock market, with the S&P 500, tracked by the SPDR S&P 500 ETF Trust (NYSE:SPY), gaining 3.2%, despite significant disparities in sector and industry performances. The technology sector, as tracked by the Technology Select Sector SPDR Fund (NYSE:XLK), led the 11 S&P 500 sectors in performance last month, surging 7.7% and achieving its strongest monthly gain this year. In stark contrast, utilities lagged, with the Utilities Select Sector SPDR Fund (NYSE:XLU) dropping 6.3%, marking the worst month since September 2023. Top Performing Industry ETFs In June The iShares Expanded Tech-Software Sector ETF (NYSE:IGV) rallied 11.3% last month, topping the rankings among industry ETFs. Hot on its heels was the VanEck Semiconductor ETF (NYSE:SMH), which climbed 8.4%, showcasing strong momentum in the semiconductor sector. Since hitting its low ...Full story available on Benzinga.com

  Benzinga

  Featured Companies: ADBE ALNY AVGO COPX CRWD IBB IGV OLED ORCL QRVO REZ SCLX SMH SOXX SPY XBI XLK XLU XSD
• Avidity (RNA) Up 33% on Rare Muscle Disease Study Results

  Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.

  Zacks Investment Research

  Featured Companies: ARQT HRTX
• A Glimpse Into The Expert Outlook On Avidity Biosciences Through 6 Analysts

  In the last three months, 6 analysts have published ratings on Avidity Biosciences (NASDAQ:RNA), offering a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 4 0 0 0 0 3M Ago 0 1 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Avidity Biosciences, presenting an average target of $39.67, a high estimate of $60.00, and a low estimate of $33.00. This current average has increased by 15.55% from the previous average price target of $34.33. Breaking Down Analyst Ratings: A Detailed Examination The standing of Avidity Biosciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Joseph Stringer Needham Maintains Buy $35.00 $35.00 Joseph Stringer Needham Maintains Buy $35.00 $35.00 Keay Nakae Chardan Capital Maintains Buy $33.00 $33.00 Geoff Meacham B of A Securities Announces Buy $40.00 - Joseph Stringer Needham Maintains Buy $35.00 - Eric Schmidt Cantor Fitzgerald Announces Overweight $60.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it ...Full story available on Benzinga.com

  Benzinga
• 2 Potentially High-Reward Growth Stocks to Buy Right Now

  These two biotechnology stocks could be gearing up for a run.

  The Motley Fool

  Featured Companies: LRMR
• Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates

  Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -540% and 24.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: CHRS